A new approach for 'deep salvage' trials in advanced HIV infection.
One of the most difficult problems in HIV care today is the management of individuals infected with multidrug-resistant viruses. Well-controlled, carefully designed clinical trials have recently resulted in the approval of several new antiviral agents for the treatment of drug-resistant HIV. The design of these trials has come at the cost of the predictable emergence of drug-resistant viruses among individuals randomly assigned to receive a suboptimal revised treatment regimen. We propose here a different approach to the evaluation of drug efficacy in individuals harbouring multidrug-resistant HIV.
Lederman
Michael M
MM
Center for AIDS Research, Case Western Reserve University, University Hospitals of Cleveland, Cleveland, Ohio, USA.
Miller
Veronica
V
Weller
Ian
I
Deeks
Steven G
SG
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D024921:Drug Resistance, Multiple, Viral; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D012107:Research Design; D016879:Salvage Therapy / Q000379:methods*
D019380:Anti-HIV Agents